ArticleCancer chemotherapy and pharmacology2026
Prospective monitoring of plasma abemaciclib in breast cancer patients: associations with age and adverse events.
Article in Cancer chemotherapy and pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePlasma abemaciclib concentrations vary among individuals, and their association with hematologic toxicity has been reported in real-world settings. The incidence of interstitial lung disease (ILD), a serious adverse event of abemaciclib, is higher in clinical practice than in clinical trials. Here, to assess the potential usefulness of abemaciclib concentration monitoring, we conducted a prospective exploratory study of the association between plasma abemaciclib concentration, age, and the occurrence of adverse events in breast cancer patients.
methodsPatients with hormone receptor-positive breast cancer who initiated abemaciclib with endocrine therapy between December 2022 and May 2025 were included. Plasma abemaciclib concentrations were measured using liquid chromatography-tandem mass spectrometry, and adverse events of grade ≥ 3 or those leading to treatment interruption were identified.
resultsA total of 322 plasma samples from 23 patients were analyzed. The median age was 52 years (range: 34-79), including four aged ≥ 65. Thirteen had metastatic disease, and six out of ten completed two-year adjuvant therapy. During a median follow-up of 344 days (range: 29-732), ILD occurred in five patients (21.7%). Abemaciclib concentrations on day 15 of cycle 1 were significantly higher in patients with ILD than in those without (p = 0.005, Mann-Whitney U test). A positive correlation was observed between age and concentration on day 15 of cycle 1 (Pearson's correlation coefficient = 0.54, p = 0.008), with increased variability in older patients.
conclusionAbemaciclib concentrations tend to be higher in elderly patients and may be associated with increased risk of ILD. These findings support the potential usefulness of abemaciclib concentration monitoring from a safety perspective in real-world practice.
Indexed as
Identifiers
41484396What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.